CD8A and cancer: In one study, Dey et al. developed 3D tumor-T cell platforms that allowed for the study of complex immune-cancer interactions and the evaluation of genetically engineered CD8+ T cells expressing mucosal-associated invariant T (MAIT) cell receptors against breast cancer cells (73).